NanoActive Olmesartan Medoxomil


Bioavailability of orally administered Olmesartan Medoxomil is limited by its very low aqueous solubility. In vitro solubility tests showed that formulation of Olmesartan Medoxomil with the NanoActiveâ„¢ technology resulted in significant improvement of apparent solubility (figure 1).

Improvement in apparent solubility and dissolution resulted in a substantial increase in oral bioavailability when compared to the unformulated reference Olmesartan Medoxomil. Exposure (AUC) and maximal plasma concentration (cmax) showed several fold increase in rat studies under fasted conditions (figure 2).

Solubility enhancement of Olmesartan Medoxomil by
the NanoActiveâ„¢ Technology Platform

Figure1
Serum concentrations of Olmesartan Medoxomil after oral
administration of 20 mg/kg NanoActive Olmesartan Medoxomil
and reference test substance in rats under fasted condition

Figure2